Carisma Therapeutics Inc. financial data

Symbol
CARM on OTC
Location
Philadelphia, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 113% % -72%
Return On Equity -29% % 97%
Return On Assets 55% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41,845,078 shares 0.23%
Common Stock, Shares, Outstanding 41,788,096 shares 0.09%
Entity Public Float $53,095,128 USD -81%
Common Stock, Value, Issued $41,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 41,788,096 shares 0.48%
Weighted Average Number of Shares Outstanding, Diluted 41,940,292 shares 0.85%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $45,300,000 USD 1232%
Research and Development Expense $27,355,000 USD -57%
General and Administrative Expense $14,430,000 USD -39%
Operating Income (Loss) $10,847,000 USD
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $8,042,000 USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,777,000 USD -90%
Cash, Cash Equivalents, and Short-term Investments $2,800,000 USD -90%
Assets, Current $5,870,000 USD -83%
Operating Lease, Right-of-Use Asset $684,000 USD -71%
Assets $6,554,000 USD -84%
Accounts Payable, Current $5,571,000 USD 222%
Employee-related Liabilities, Current $829,000 USD -64%
Accrued Liabilities, Current $1,088,000 USD -76%
Liabilities, Current $6,812,000 USD -35%
Operating Lease, Liability, Noncurrent $609,000 USD -20%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $7,421,000 USD -86%
Retained Earnings (Accumulated Deficit) $279,902,000 USD 2.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $867,000 USD 92%
Liabilities and Equity $6,554,000 USD -84%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,067,000 USD 55%
Net Cash Provided by (Used in) Financing Activities $626,000 USD -146%
Net Cash Provided by (Used in) Investing Activities $524,000 USD
Common Stock, Shares Authorized 350,000,000 shares 0%
Common Stock, Shares, Issued 41,788,096 shares 0.09%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,777,000 USD -90%
Interest Paid, Excluding Capitalized Interest, Operating Activities $33,000 USD -34%
Deferred Tax Assets, Valuation Allowance $153,855,000 USD 15%
Deferred Tax Assets, Gross $155,132,000 USD 15%
Operating Lease, Liability $762,000 USD -65%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $60,477,000 USD 30%
Lessee, Operating Lease, Liability, to be Paid $939,000 USD -61%
Operating Lease, Liability, Current $153,000 USD -89%
Lessee, Operating Lease, Liability, to be Paid, Year Two $233,000 USD 3.1%
Lessee, Operating Lease, Liability, to be Paid, Year One $226,000 USD 3.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 10%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $177,000 USD -38%
Lessee, Operating Lease, Liability, to be Paid, Year Three $240,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $87,742,000 USD 21%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $184,000 USD -23%
Operating Lease, Payments $707,000 USD -52%
Additional Paid in Capital $278,994,000 USD 0.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,277,000 USD 9.2%
Share-based Payment Arrangement, Expense $2,212,000 USD -40%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%